择期植入物乳房再造中接受抗血栓药物治疗的患者发生重大血栓并发症风险高
匹配后2024例患者中,用药者90天全因血栓缺血并发症风险显著升高(HR 5.62,95%CI 3.53-8.95,p<0.0001),深静脉血栓、肺栓塞、心肌梗死、卒中及输血风险亦显著增加。作者认为需进一步监测并可能需多学科干预。
要点
- 择期植入物乳房再造前使用抗血栓药物者90天血栓缺血并发症风险升高(HR 5.62)。
- 用药者90天深静脉血栓、肺栓塞、心肌梗死、卒中风险均显著增加。
- 使用抗血小板药、直接口服抗凝药或华法林者输血风险显著增加。
核心结论
- 接受抗血栓药物治疗的择期植入物乳房再造患者发生危及生命的血栓事件及输血的风险显著增加。
- 作者认为这提示需要进一步监测,并可能需多学科及跨学科干预以帮助降低该风险。
- 作者提出这些干预可作为未来前瞻性研究的主题。
研究设计与样本
- 将处方治疗性抗血栓药物的患者与未处方者按与出血及血栓缺血事件独立相关的合并症进行一对一匹配。
- 采用Cox比例风险模型分析植入物乳房再造后90天出血及重大血栓缺血事件风险。
主要发现
- 36379例接受植入物乳房再造的患者中,2024例按年龄及高危合并症完美匹配。
- 处方抗血栓药物者90天全因血栓缺血并发症风险增加(HR 5.62,95%CI 3.53-8.95,p<0.0001)。
- 处方抗血栓药物者90天深静脉血栓、90天肺栓塞、90天心肌梗死及90天卒中风险显著增加。
- 处方抗血小板药物、直接口服抗凝药(DOAC)及华法林者输血风险显著增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Implant-based reconstruction (IBR) is the most frequently performed breast reconstruction procedure in the USA. As the US population ages, an increasing number of these patients suffer from comorbidities requiring the use of chronic antithrombotic therapy. Outcomes following IBR in patients prescribed these medications are not well understood. MATERIALS/PATIENTS AND METHODS: An all-payor administrative claims database (52 million patients) was queried for patients undergoing IBR from 2010 through 2018. Patients who were prescribed therapeutic antithrombotic therapy, and those who were not, were matched in a one-to-one fashion for comorbidities independently associated with bleeding and thrombo-ischemic events following first-stage IBR. Cox proportional hazards models investigated the 90-day risk of bleeding and major thrombo-ischemic events following IBR. RESULTS: Of the 36,379 patients found to have undergone IBR, 2,024 patients were perfectly matched for age and high-risk comorbidities. Patients prescribed antithrombotic drugs had increased 90-day risk for all thrombo-ischemic complications (HR: 5.62, 95% CI: 3.53-8.95, p < 0.0001), as well as a significantly increased risk for 90-day DVT, 90-day PE, 90-day myocardial infarction, and 90-day stroke. Patients specifically prescribed antiplatelet drugs, direct oral anticoagulants (DOAC), and warfarin had a significantly increased risk for transfusion. CONCLUSION: Patients prescribed antithrombotic therapy had a significantly increased risk for life-threatening thrombotic events and transfusion following elective IBR. This suggests a role for further monitoring and a potential role for multi- and interdisciplinary interventions to help mitigate this risk. These interventions can be the subject of future prospective studies.
引用
- Wiegmann AL, Khalid SI, Alba BE, et al. Patients prescribed antithrombotic medication in elective implant-based breast reconstruction are high risk for major thrombotic complications. J Plast Reconstr Aesthet Surg. 2022. PMID: 35879206. doi:10.1016/j.bjps.2022.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。